Literature DB >> 3531211

The purification of fully active recombinant transforming growth factor alpha produced in Escherichia coli.

M E Winkler, T Bringman, B J Marks.   

Abstract

Recombinant human transforming growth factor alpha (TGF alpha), which is active as assessed by competition with epidermal growth factor (EGF) for binding to the EGF receptor, has been produced in Escherichia coli and separated from misfolded and inactive forms of recombinant TGF alpha using reverse-phase high performance liquid chromatography. The purified recombinant TGF alpha was used to produce a monoclonal antibody that binds to active TGF alpha specifically. The antibody was coupled to Sepharose and used as an independent method for purifying active TGF alpha. The EGF receptor binding activity of antibody affinity purified TGF alpha is comparable to that of high performance liquid chromatography-purified active TGF alpha, and is 0.55 mg of EGF eq/mg of TGF alpha. The disulfide arrangement of the active TGF alpha was determined after digestion with thermolysin, and found to be analogous to the disulfide arrangement previously determined for EGF (Savage, C. R., Hash, J. H., and Cohen, S. (1973) J. Biol. Chem. 248, 7666-7672).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531211

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimaeras: correlation with receptor routing after ligand-induced internalization.

Authors:  A E Lenferink; R H Kramer; M J van Vugt; M Königswieser; P P Di Fiore; E J van Zoelen; M L van de Poll
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 2.  The multiple roles of epidermal growth factor repeat O-glycans in animal development.

Authors:  Amanda R Haltom; Hamed Jafar-Nejad
Journal:  Glycobiology       Date:  2015-07-14       Impact factor: 4.313

3.  The fifth epidermal growth factor-like domain of thrombomodulin does not have an epidermal growth factor-like disulfide bonding pattern.

Authors:  C E White; M J Hunter; D P Meininger; S Garrod; E A Komives
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

4.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

5.  Transforming growth factor alpha and a PC12-derived growth factor induce neurites in PC12 cells and enhance the survival of embryonic brain neurons.

Authors:  M B Zhang; D D Woo; B D Howard
Journal:  Cell Regul       Date:  1990-06

6.  Substitution of lysine for arginine at position 42 of human transforming growth factor-alpha eliminates biological activity without changing internal disulfide bonds.

Authors:  D Defeo-Jones; J Y Tai; G A Vuocolo; R J Wegrzyn; T L Schofield; M W Riemen; A Oliff
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  Aromaticity at position 37 in human epidermal growth factor is not obligatory for activity.

Authors:  D A Engler; M R Hauser; J S Cook; S K Niyogi
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

8.  Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities.

Authors:  E Lazar; S Watanabe; S Dalton; M B Sporn
Journal:  Mol Cell Biol       Date:  1988-03       Impact factor: 4.272

9.  Structure-function analysis of synthetic and recombinant derivatives of transforming growth factor alpha.

Authors:  D Defeo-Jones; J Y Tai; R J Wegrzyn; G A Vuocolo; A E Baker; L S Payne; V M Garsky; A Oliff; M W Riemen
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

10.  Sequence-specific 1H-NMR assignments and identification of two small antiparallel beta-sheets in the solution structure of recombinant human transforming growth factor alpha.

Authors:  G T Montelione; M E Winkler; L E Burton; E Rinderknecht; M B Sporn; G Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.